Kura Oncology And Mirati Therapeutics Enter Into Clinical Collaboration And Supply Agreement To Evaluate KO-2806 And Adagrasib For Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology and Mirati Therapeutics have entered into a clinical collaboration and supply agreement to evaluate KO-2806 and Adagrasib for non-small cell lung cancer.
November 02, 2023 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kura Oncology has entered into a clinical collaboration with Mirati Therapeutics, which could potentially enhance its product portfolio and market position.
The collaboration with Mirati Therapeutics could potentially enhance Kura Oncology's product portfolio and market position. This could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Mirati Therapeutics has entered into a clinical collaboration with Kura Oncology, which could potentially enhance its product portfolio and market position.
The collaboration with Kura Oncology could potentially enhance Mirati Therapeutics' product portfolio and market position. This could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100